Revolution Medicines, Inc. (RVMD) earnings date

Nasdaq · Large cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 36 days, typically, give or take 9 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Wed, Nov 4, 2026after close 35 8-K
Q2 FY2026Wed, Aug 5, 2026after close 36 8-K
Q1 FY2026Wed, May 6, 2026after close 36 8-K
Q4 FY2025Wed, Feb 25, 2026after close 56 8-K
Q3 FY2025Wed, Nov 5, 2025after close 36 8-K
Q2 FY2025Wed, Aug 6, 2025after close 37 8-K
Q1 FY2025Wed, May 7, 2025after close 37 8-K
Q4 FY2024Wed, Feb 26, 2025after close 57 8-K

What they guided beta

Q3 FY2026 "Longer-term follow-up from the ongoing Phase 1 trial evaluating daraxonrasib in combination with gemcitabine and nab-paclitaxel in treatment-naïve metastatic pancreatic cancer will be shared in a late-breaking oral presentation at the EORTC-NCI-AACR (ENA) Symposium, building on findings previously presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2026." exhibit
Q3 FY2026 "Global enrollment is expected to be completed in the first half of 2027." exhibit
Q3 FY2026 "Global enrollment in RASolve 301, the Phase 3 trial evaluating daraxonrasib in this setting, is winding down with all sites expected to close enrollment by the end of November 2026, supporting an anticipated initial readout in 2027." exhibit
Q3 FY2026 "Revolution Medicines expects to provide a clinical data update from its earlier phase CRC studies along with the RASonate 312 trial design in the first half of 2027." exhibit
Q3 FY2026 "The company expects to report initial clinical monotherapy data in 2027." exhibit
Q2 FY2026 "Enrollment in the global Phase 3 RASolve 301 trial evaluating daraxonrasib in patients with previously treated RAS mutant NSCLC is expected to be completed this year, supporting an anticipated initial readout in 2027." exhibit
Q2 FY2026 "These findings support the planned global Phase 3 RASolve 307 study evaluating elironrasib in combination with standard of care for patients with first-line metastatic RAS G12C NSCLC, which the company expects to initiate in the fourth quarter of 2026." exhibit
Q2 FY2026 "The company expects to provide updated clinical data and additional visibility into its CRC development strategy during the fourth quarter of 2026." exhibit
Q2 FY2026 "The company remains on track to identify a recommended Phase 2 dose during the second half of 2026 and expects to share initial clinical data in 2027." exhibit
Q2 FY2026 "Innovative New Class of RAS(ON) Inhibitors The company also remains on track to initiate a first-in-human clinical trial evaluating RM-055, a representative from a novel class, during the fourth quarter of 2026." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/RVMD
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/RVMD

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

RVMD earnings date badge

HTML

<a href="https://veritasdata.dev/company/RVMD/"><img src="https://veritasdata.dev/embed/RVMD.svg" alt="RVMD earnings date" width="240" height="56"></a>

Markdown

[![RVMD earnings date](https://veritasdata.dev/embed/RVMD.svg)](https://veritasdata.dev/company/RVMD/)

Script

<script async src="https://veritasdata.dev/embed/RVMD.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/RVMD"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.